ImmuPharma (IMM) Stock Statistics & Valuation Metrics

ImmuPharma has a market cap or net worth of £13.34M. The enterprise value is ―.

ImmuPharma has 499,723,940 shares outstanding. The number of shares has decreased by -2.65% in one year.

ImmuPharma’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.

The current PE Ratio of ImmuPharma is ―. ImmuPharma’s PEG ratio is ―.

In the last 12 months, ImmuPharma had revenue of 0.00 and earned -2.92M in profits. Earnings per share was -0.01.

In the last 12 months, operating cash flow was -1.59M and capital expenditures 2.00, giving a free cash flow of -1.59M billion.

ImmuPharma pays an annual dividend of ―, resulting in a dividend yield of ―

ImmuPharma upcoming earnings date is Sep 25, 2025, TBA Not Confirmed.

ImmuPharma as a current ratio of ―, with Debt / Equity ratio of ―

In the past 12 months, ImmuPharma has paid -497.10K in taxes.

ImmuPharma EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.

ImmuPharma has £1.08M in cash and marketable securities with £0.00 in debt, giving a net cash position of -£1.08M billion.

Gross margin is ―, with operating margin of ―, and net profit margin of ―.

The average price target for ImmuPharma is ―, which is 11.43% higher than the current price. The consensus rating is ―